Immunotherapy in Lung Cancer Articles | Page 2

Nivolumab Improves Survival in Pretreated Chinese NSCLC Patients
Nivolumab improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non-small cell lung cancer.
Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer
George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.
Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval
The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.
Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC
The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer. 
NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
 
Immunotherapy Impact Extends to Mesothelioma
Gerard Zalcman, MD, discusses the promise of immunotherapy in patients with mesothelioma.
Expert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLC
Marina C. Garassino, MD, discusses the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and the role of combination therapy.
Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC
Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer.
Progression Issues Surface With NSCLC Immunotherapy
Paul A. Bunn Jr, MD, discusses strategies for analyzing and responding to signs of progression for patients receiving immunotherapy for non-small cell lung cancer.
Lawrence E. Feldman, MD, discusses first- and second-line therapy with checkpoint inhibitors in NSCLC, and the promise that emerging combinations could have on the field.
Publication Bottom Border
Border Publication
x